Parkinson DiseasePlacebo EffectDouble-Blind Methodalpha-SynucleinAntiparkinson AgentsContraceptives, OralParkinsonian DisordersParkinson Disease, SecondaryContraceptives, PostcoitalLevodopaContraceptives, Oral, CombinedGlucosylceramidaseContraceptives, Oral, HormonalSubstantia NigraLewy BodiesTreatment OutcomeDeep Brain StimulationCross-Over StudiesMultiple System AtrophyDopamineContraception, Postcoital1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineDopaminergic NeuronsOxidopamineContraceptive Agents, FemaleContraception BehaviorSubthalamic NucleusLewy Body DiseaseNeurodegenerative DiseasesContraceptionMPTP PoisoningGait Disorders, NeurologicSupranuclear Palsy, ProgressivePostural BalanceEthinyl EstradiolMedication AdherenceDesogestrelAdministration, OralSeverity of Illness IndexDrug PackagingTime FactorsDance TherapyDrugs, Chinese HerbalContraceptive Devices, FemaleContraceptives, Oral, SyntheticPatient CompliancePutamenBrainEssential TremorUbiquitin-Protein LigasesDrug Therapy, CombinationNeuronsTabletsContraceptive AgentsDose-Response Relationship, DrugPedunculopontine Tegmental NucleusPergolideContraceptive DevicesGaitREM Sleep Behavior DisorderOncogene ProteinsGaucher DiseaseTyrosine 3-MonooxygenaseDrug Administration ScheduleRandomized Controlled Trials as TopicAnalysis of VarianceCarbidopaFollow-Up StudiesProspective StudiesNerve DegenerationDementiaClinical Trials as Topicbeta-SynucleinCorpus StriatumHypokinesiaMovement DisordersNorpregnenesCase-Control StudiesNeuroprotective AgentsNeuropsychological TestsQuestionnairesGlobus PallidusMesencephalonGenetic Predisposition to DiseaseAge of OnsetMutationSingle-Blind MethodManebNorgestrelPilot ProjectsRisk FactorsMenstruationDyskinesiasDisease Models, AnimalDrug CombinationsTropanesMitochondriaDopamine AgonistsDopamine Agents1-Methyl-4-phenylpyridinium